%0 Journal Article
%T Erectile Dysfunction among Diabetic Men in Two Medical Centers in Burkina Faso: Epidemiological, Diagnosis and Therapeutic Aspects
%A Timoth¨¦e Kambou
%A Cyprien Zar¨¦
%A Abdoul Karim Par¨¦
%A Adama Ouattara
%A Youomb¨¨viel Ludovic Som¨¦
%A Bakary Gustave Sanon
%J Advances in Sexual Medicine
%P 1-5
%@ 2164-5205
%D 2014
%I Scientific Research Publishing
%R 10.4236/asm.2014.41001
%X <span>Objective: </span><span>To</span><span> </span><span>study erectile dysfunction in diabetic patients seen in two clinic</span><span>s</span><span> in the city of Bobo-Dioulasso, Burkina Faso. </span><span>Materials and Methods:</span><span> </span><span>A prospective cross-sectional descriptive study was conducted at the</span><span> </span><span>Souro</span><span> </span><span>Sanou</span><span> </span><span>Teaching Hospital (CHUSS) and the Saint Leopold clinic in</span><span> </span><span>Bobo-Dioulasso, from March 1 to September 1, 2012. </span><span>A total of 107 patients data</span><span> </span><span>were</span><span> </span><span>collated and analysed, which</span><span> </span><span>was</span><span> </span><span>then</span><span> </span><span>grouped</span><span> </span><span>into</span><span> </span><span>two</span><span>: the ED group, designating patients with erectile dysfunction and the NED group consisting of those patients without. The sample comprised of 61 patients with type</span><span>s</span><span> 1 and 2 diabetes</span><span>and were</span><span> </span><span>aged</span><span> </span><span>between 25</span><span>-</span><span>70 years.</span><span> The IIEF-5 was used to evaluate erectile dysfunction. </span><span>Results: </span><span>The prevalence of erectile dysfunction was 57%. The average age of patients was 54.4 ¡À 8.3 years. All patients with ED had type 2 diabetes. The mean disease duration of diabetes was 7.2 ¡À 6 years. Erectile dysfunction was severe in 32.8% of cases, moderate in 31.1% of cases and mild in 36.1%. Its severity was significantly associated with glycated hemoglobin, triglycerides and BMI. Phosphodiesterase types 5 (PDE5) inhibitors were found to be effective in the treatment of erectile dysfunction with a satisfactory therapeutic response in 77.4% of users.</span><span> </span><span>Conclusion:</span><span> </span><span>Erectile dysfunction is a common complication in diabetic patients. Its occurrence and severity </span><span>are</span><span> influenced by several factors. The potential presence of this disorder should be assessed</span><span> </span><span>due to its negative impact on quality of life.</span><span> </span><span>Phosphodiesterase type 5 inhibitors</span><span> </span><span>are an effective treatment modality in diabetic patients.</span>
%K Erectile Dysfunction
%K Diabetes
%K Phosphodiesterase Type 5 Inhibitors
%K Bobo-Dioulasso
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=41602